anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A multicenter, open label, descriptive study. Five hundred requiring contraception will receive the weekly transdermal contraceptive patch for 6 cycles. At the baseline and after the 1st, 3rd and 6th cycles, satisfaction with the method will be assessed. The contraceptive efficacy will be assessed by the Pearl Index and by life table analysis. To assess satisfaction with the weekly transdermal contraceptive patch, this method will be compared to the previous contraceptive method. Adhesion, cycle control, safety and efficacy are secondary outcomes. Treatment duration: 6 cycles (4 weeks each). The subject will wear a 20 cm2 contraceptive transdermal patch for one full week, apply a fresh patch for week 2, and a third patch for week 3. The fourth week will be patch-free. Each patch deliveries 150 mcg of NLGM and 20 mcg of EE per day.
Hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
PURPOSE:The titled cosmetic capable of molding cosmetic such as face powder, etc. variously, having good durability of makeup, capable of preventing contamination caused by microorganism, obtained by blending a component such as powder base, etc. with gel of an organic gel-forming agent, a volatile oily base and/or an organic solvent, drying the blend into a solid state. CONSTITUTION:A powder base such as talc, kaolin, etc. and other components are blended with preferably 5-50wt% based on powder base of gel (1-30wt%) of an organic gel-forming agent, a volatile oily base and/or an organic solvent, and dried and solidified. The drying and solidification are carried out for each of pressing mold, and the blend is dried at 40-100 deg.C. Dextrin fatty acid ester, quaternary ammonium salt of cellulose sulfate, metallic soap of fatty acid, and aluminum, magnesium, or zinc, polyethylene, organic bentonite, etc. may be preferable as the organic gel-forming agent.
A system and method for image data management. A tiled representation of a data set is accessed. The tiled representation includes a plurality of high-resolution tiles and a plurality of reduced-resolution tiles. A request to access said data set from a computing device is received. An image display window is determined based on said request from the computing device, where the image display window corresponds to a displayable image for display on the display device. At least one overlapping image to send the computing device is determined based on said image display window, where the at least one overlapping image is selected from the scaled full images, the plurality of high-resolution tiles, and the plurality of reduced resolution tiles. At least a portion of the at least one overlapping image is sent to the computing device.
CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + high dose IL-2.
Group (A): will receive rehabilitation program with exposure to ExMS, Patients will receive regular sessions of electromagnetic stimulation using Magneto STYM device, (Iskra medical d.o.o, Slovenia). Each session will last for 20 minutes. Patients will receive three weekly sessions for total of 20 sessions starting one month after catheter removal.
Chimeric antigen receptor T cell (CART) is a kind of engineered immunotherapy by transferring an artificial antigen binding receptor and also intercellular co-stimulating molecules into T cells. This kind of engineered T cells gains the ability to recognize antigen specific tumor cells and initiate the killing process in a HLA-independent way. CD19 is the specific cellular marker of B lineage acute leukemia (B-ALL), thus CD19-CART will be efficient in treating B lineage ALL. The investigators have constructed two kinds of CD19-CART. One is equipped with a murine CD19 scFv (single-chain variable fragmentt), while the other with a humanized scFv. This study aims to evaluate the safety and efficacy of both murine and humanized CD19-CART in treating refractory or recurrent ALL.
The invention discloses a medicine for external application for stopping bleeding and treating scald. The medicine comprises the following raw materials in parts by weight: 15-28 parts of longan seeds, 10-16 parts of folium artemisiae argyi, 5-8 parts of panax notoginseng, 9-15 parts of madders, 6-16 parts of crude pollen typhae, 19-27 parts of cottonrose hibiscus leaves, 5-9 parts of tung oil, 4-12 parts of sedum lineare, 2-9 parts of borneol, 5-16 parts of olibanum, 7-14 parts of aloe, 9-18 parts of rheum officinale, 2-6 parts of dried alum and 5-8 parts of ladder brake. The preparation method comprises the following steps: weighing the raw materials in parts by weight, and cleaning and airing the raw materials; carbonizing the ladder brake and rheum officinale by stir-frying for later use; preparing folium artemisiae argyi into folium artemisiae argyi processed with vinegar; and after grinding longan seeds, folium artemisiae argyi, panax notoginseng, madders, crude pollen typhae, cottonrose hibiscus leaves, sedum lineare, borneol, olibanum, aloe and dried alum, adding charked ladder brake, rheum officinale, folium artemisiae argyi processed with vinegar and tung coil and continuously grinding to obtain the medicine. The medicine disclosed by the invention can quickly stop bleeding. When the medicine is used for treating scald, the local temperature can be quickly reduced to prevent secondary damages and further play roles of locally sterilizing and disinfecting. The medicine has the characteristics of being high in radical rate, free of incrustation and color stains and the like.
Patient is intubated with etomidate 0.1\~0.2mg/kg and rocuronium 1mg/kg. 30 minutes after rocuronium administration, patient is administered neostigmine 0.05mg/kg + glycopyrrolate 0.01mg/kg. Glasgow coma scale as neurologic assessment is assessed at 10-minute intervals before intubation, and at 5-minute intervals up to 30 minutes after administration of neostigmine. After 30 minutes, the assessments are conducted at 10-minute intervals. Additionally, if the patient spontaneously opens their eyes, the GCS is assessed at that specific moment. The GCS evaluation continues until the patient reaches a point of responsiveness, indicated by a Motor score of 6 on the GCS.
Patients who underwent same surgery from the January 2008 to July 2015 but have not had recurrence in the five-year follow-up period (non-recurrent group, NRG) were accepted eligible. They were evaluated for erroneous off-midline closures as an exposure variable.
INTRODUCTION: Morbidity from an emergency laparotomy (EmLap) is difficult to define and poorly understood. Morbidity is a holistic concept, reliant upon an interplay of bio-psychosocial outcomes that evolve long after discharge. To date, no previous study has explored the psychosocial outcomes following EmLap as a collective, nor their change over time. This study aims to describe the holistic morbidity following EmLap within the first year following surgery.
METHODS AND ANALYSIS: This is a multicentre, mixed-methods prospective 12-month cohort study with two participant populations: patient participants and family caregivers (FCGs). A target of 160 adult patients who undergo EmLap and can give informed consent will be included in the patient participant group. Patient participants will be asked to complete three patient surveys, incorporating validated patient-reported outcome measures (PROMs) to assess bio-psychosocial outcomes (EuroQol five-dimension five-level (EQ5D-5L), Gastrointestinal Quality Life Index-36, Patient Health Questionnaire-9, Generalised Anxiety Disorder 7, International Trauma Questionnaire, Caregiver Interaction Scale and Fatigue Severity Scale) in the 12 months following surgery. A subgroup of 15 patient participants will be asked to take part in two semistructured interviews at 6 and 12 months. A target of 15 associated family caregivers will be included in the FCG group. FCGs will be asked to take part in a semi-structured interview at 6 months to assess the EmLap impact on the wider support network. The primary outcome will be a change in quality of life (EQ5D-5L) at 12 months. Secondary outcomes will be changes in bio-psychosocial status at 3 and 12 months. Qualitative analysis will allow contextualisation of PROMS and further explore themes of EmLap morbidity. It is anticipated that the results of this study will help inform and develop standards of aftercare for future EmLap patients.
ETHICS AND DISSEMINATION: This study has received ethical approval (Wales REC7;12/WA/0297) and will be undertaken in accordance with the principles of Good Clinical Practice. We intend to disseminate study results in peer-reviewed journals and medical conferences, as well as a lay report to study participants.
TRIAL REGISTRATION NUMBER: Clinical Trials.gov NCT05281627.
Veterans with post-traumatic stress disorder (PTSD) frequently have insomnia (trouble falling or staying asleep). Untreated insomnia carries grave health consequences. Early evidence suggests that pimavanserin (Nuplazid), a medication approved by the Food and Drug Administration for the treatment of psychosis (hallucinations and delusions) in Parkinson's Disease, may treat insomnia. In this preliminary study, Veterans with insomnia and PTSD will receive either pimavanserin 34mg or placebo at bedtime for 8 weeks, and sleep quality will be compared pre- and post-treatment. Veterans will also complete sleep studies and wear actigraphy watches so we may better appreciate how pimavanserin impacts sleep. Overall, this study will help us understand pimavanserin's potential benefit for treating PTSD-related insomnia and prepare for a larger, future trial.
BACKGROUND: The article describes the potential use of an original model called the layered epidemiological assessment (warstwowa ocena epidemiologiczna - WOE) for assessing the potential risk of infections in facilities intended for elderly individuals.
MATERIAL AND METHODS: To verify the possibility of using the WOE method for assessing epidemiological safety hazards in the built environment, available literature sources related to the legal requirements in Poland regarding the assessment of medical facility ergonomics in terms of infection transmission were analyzed. The article also referred to the guidelines of the New European Bauhaus and the Baukultur Quality System as a standardized method for assessing the quality of the built environment. The article presents the fundamental assumption of the author's WOE method, which allows for the assessment of the risk of infection transmission separately for each component of a building. The effectiveness of the method was demonstrated by using it to assess the risk of infections in a geriatric ward room as an example.
RESULTS: The article demonstrates that by employing the WOE, it is possible to clearly differentiate potential infection routes within the analyzed facilities and assign them to specific building components. Furthermore, by applying the presented method, it is possible to define necessary procedures and develop action plans to minimize the risk of infection spread within the analyzed properties.
CONCLUSIONS: The application of the WOE for evaluating architectural solutions in facilities intended for the elderly offers several benefits. The WOE method presented in the article can serve as an expert tool for quick and precise assessment of potential epidemiological hazards. An important advantage of the WOE method is its ability to be used separately for different types of epidemiological hazards characterized by different routes of infection transmission. Med Pr Work Health Saf. 2024;75(3):199-209.
Postoperative pulmonary complications (PPC) are common after lung resection surgery, with an incidence that ranges between 11-32%. As PPC are associated with worse outcomes, many studies aim to find predictors that identify high risk patients and prompt specific interventions and/or monitoring and hence, improve outcomes. PPC result from lung injury inherent to lung resection surgery. Lung aeration changes seen with lung ultrasound (LUS) could detect lung injury and thus, identify patients at high risk of PPC. The underlying mechanisms of lung injury are different in the dependent and non-dependent lung; oxidative stress in both lungs, lung injury associated with one-lung ventilation in the dependent lung and ischemia/reperfusion or surgical manipulation in the non-dependent lung. LUS evaluates the dependent and non-dependent lung separately and so it can be valuable in understanding the characteristics and intensity of lung injury in each lung specifically.

This is a prospective, single-centre, observational study in which 30 consecutive participants with non-small cell lung cancer scheduled for lobectomy will be recruited. Participants will be divided in two groups depending on the surgical approach. First group will be lobectomy via thoracotomy. Second group will be lobectomy via VATS. Participants will be recruited consecutively until there are 15 patients in each group. LUS will be performed in each participant's operated and non-operated lung at three predefined time points: before surgery, after extubation and 24 h after surgery. Each hemithorax will be divided into 6 areas: anterior, lateral and posterior, separated by the anterior and posterior axillary lines, each divided into upper and lower zones. For each echographic examination, cineloops of the most pathological findings in each area will be stored and analysed offline by two independent and blinded anaesthesiologists. From these, a semiquantitative score, the modified lung ultrasound score (mLUSS), will be calculated for each hemithorax to assess lung aeration at each time point. The level of agreement for mLUSS will be tested. At the same predefined time points blood plasma samples will be collected, flash-frozen and stored in order to measure levels of the inflammatory mediators IL-6, IL-10 and TNFα.

The investigators hypothesise that LUS can detect lung injury after lung resection surgery. The primary objective of the study is to assess changes in lung aeration after lung resection with mLUSS. Secondary objectives are, first, to describe LUS findings after lung resection surgery, second, to assess the ability of mLUSS to detect oxygenation changes after lung resection and third, to compare the behaviour of inflammatory mediators in plasma with mLUSS changes.
Pelabresib (CPI-0610), a BET protein inhibitor, is in clinical development for hematologic malignancies, given its ability to target NF-κB gene expression. The MANIFEST phase 1 study assessed pelabresib in patients with acute leukemia, high-risk myelodysplastic (MDS) syndrome, or MDS/myeloproliferative neoplasms (MDS/MPNs) (NCT02158858). Forty-four patients received pelabresib orally once daily (QD) at various doses (24-400 mg capsule or 225-275 mg tablet) on cycles of 14 d on and 7 d off. The most frequent drug-related adverse events were nausea, decreased appetite, and fatigue. The maximum tolerated dose (MTD) was 225 mg tablet QD. One patient with chronic myelomonocytic leukemia (CMML) showed partial remission. In total, 25.8% of acute myeloid leukemia (AML) patients and 38.5% of high-risk MDS patients had stable disease. One AML patient and one CMML patient showed peripheral hematologic response. The favorable safety profile supports the ongoing pivotal study of pelabresib in patients with myelofibrosis using the recommended phase 2 dose of 125 mg tablet QD.CLINICAL TRIAL REGISTRATION: NCT02158858.
Artificial tooth parts, e.g. crowns, inlays, and dental bridges are made by coating an appropriate support layerwise with suitable plastically deformable polymerizable masses, each layer being at least partially polymerized before the application of the next layer. Liquid monomers which may be used in the polymerizable masses, optionally with fillers, colouring materials, and dry powdered polymers, e.g. polymethyl methacrylate and a methyl methacrylate-allyl methacrylate copolymer, include diallyl fumarate, cyclohexyl methacrylate, tetrahydrofurfuryl methacrylate, tri-, tetra- and other polyethylene glycol dimethacrylates or acrylates, trimethylol propane trimethacrylate, 1,3 butyleneglycol dimethacrylate, diallyl phthalate and cyanuric acid triallyl ester. Polymerization may be effected by the application of heat and/or radiation and/or the addition of catalysts such as peroxides.ALSO:Artificial tooth parts e.g. crowns, inlays, and dental bridges are made by coating an appropriate support layerwise with suitable plastically deformable polymerisable masses, each layer being at least partially polymerised before the application of the next layer.  The support, which may be removable, may be made of metal, synthetic plastics, or plaster of Paris, and coating may be effected with a brush, spatula or spray can.  The coating compositions preferably comprise esters of an aliphatic polyhydroxy compound and acrylic acid or methacrylic acid together with fillers and colouring materials.  Methyl methacrylate polymer may be included in the polymerisable masses.ALSO:Artificial tooth parts e.g. crowns, inlays, and dental bridges, are made by coating an appropriate support in a layerwise manner with suitable plastically deformable polymerisable masses, each layer being at least partially polymerised before the application of the next layer.  Monomers which may be used in the polymerisable masses include esters of an aliphatic polyhydroxy compound and acrylic acid or methacrylic acid.  Methyl methacrylate polymer may be included in the polymerisable masses together with fillers, and colouring materials.  The support may be made of metal, synthetic plastics, or plaster of paris and coating may be effected with a brush, spatula, or spray can.  A release layer e.g. of a silicone may be applied to the support.
OBJECTIVES: Numerous prognostic models have been proposed for ovarian cancer, extending from single serological factors to complex gene-expression signatures. Nonetheless, these models have not been routinely translated into clinical practice. We constructed a robust and readily calculable model for predicting surgical outcome and prognosis of ovarian cancer patients by exploiting commonly available clinico-pathological factors and three selected serum parameters.
METHODS: Serum CA125, human epididymis protein 4 (HE4) and mesothelin (MSL) were quantified by Lumipulse® G chemiluminescent enzyme immunoassay (Fujirebio) in a total of 342 serum samples from 190 ovarian cancer patients, including 152 paired pre- and post-operative samples.
RESULTS: Detection of pre-operative HE4 and CA125 was the optimal marker combination for blood-based prediction of surgical outcome (AUC=0.86). We constructed a prognostic model, computed by serum levels of pre-operative CA125, post-operative HE4, post-operative MSL and surgical outcome. Prognostic performance of our model was superior to any of these parameters alone and was independent from BRCA1/2 mutational status. We subsequently transformed our model into a prognostic risk index, stratifying patients as "lower risk" or "higher risk". In "higher risk" patients, relapse or death was predicted with an AUC of 0.89 and they had a significantly shorter progression free survival (HR: 9.74; 95 % CI: 5.95-15.93; p<0.0001) and overall survival (HR: 5.62; 95 % CI: 3.16-9.99; p<0.0001) compared to "lower risk" patients.
CONCLUSIONS: We present a robust predictive/prognostic model for ovarian cancer, which could readily be implemented into routine diagnostics in order to identify ovarian cancer patients at high risk of recurrence.
The present invention relates to a medicament elution bracket for preventing and curing coronary disease, which belongs to the fields of a medicament and a medical appliance. The present invention aims at a cell apoptosis mechanism to select a coating medicament for the medicament elution bracket. The arsenic trioxide of the effective component of traditional Chinese medicine of arsenic (Arsenicum) is adopted as a bracket medicament. The apoptosis of smooth muscle cells in a second stage after a blood vessel is damaged is induced by the controlled release of the composite coating of polymethacrylic acid butyl ester/nanometer silicon dioxide and double PLGA coatings. The functions of different dosages of arsenic trioxide to endometrial hyperplasia after a bracket operation of a dog by controlling the medicament elution bracket are measured by pharmacokinetics in vitro and are tested by animal experiments. A result proves that the double-coating controlled release of the present invention can cause a medicament to start to be released within several hours after the medicament is implanted from the bracket and to act for a long time. Compared with the organic crosslinking agent of the prior art, the nanometer silicon dioxide in the composite coating in the bracket is safe and nontoxic to use. The controlled release elution bracket of the arsenic trioxide has the therapeutic effect of preventing and curing restenosis after the bracket operation, and has high safety.
BACKGROUND: Anal condyloma acuminatum (CA) is marked by its thorny treatment and high recurrence rate. Although 5-aminolevulinic acid photodynamic therapy (ALA-PDT) demonstrates significant efficacy and safety in treating anal CA, it does not completely prevent recurrence. This study aimed to develop and validate a nomogram model in predicting the risk of relapse in HIV-negative patients with anal CA following treatment with ALA-PDT.
METHODS: A retrospective analysis was conducted on patients diagnosed with anal CA who received combined CO2 laser vaporization and ALA-PDT between January 2013 and May 2023. Patients were divided into recurrence and non-recurrence groups. A nomogram was developed based on factors showing statistical significance in multivariable logistic regression analysis. The discriminative ability and clinical utility of the nomogram were assessed via ROC curves and decision curve analysis, with internal validation performed through bootstrap resampling.
RESULTS: Among the 176 patients included, 33 (18.75 %) experienced recurrence, while 143 did not. Independent predictors for recurrence included HPV types, history of anal intercourse, and the number of CO2 laser treatments received. Incorporating these predictors, the nomogram demonstrated a superior diagnostic performance (area under the curve = 0.881, 95 % CI: 0.818-0.935) and a significant net benefit in decision curve analysis.
CONCLUSIONS: The nomogram accurately predicts the risk of recurrence in HIV-negative patients with anal CA following ALA-PDT. It offers a valuable tool for guiding preoperative clinical decision-making and establishing personalized treatment strategies to minimize the risk of relapse.